The US Health and Human Services Department would add certain high-priced new drugs to the annual list of products targeted for price “negotiation” under an amended version of the House leadership’s drug pricing bill released 16 October.
The revision to HR 3 requires that if a new, single source drug has a wholesale acquisition cost that is...